Sichuan Kelun Pharmaceutical (002422) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and strategy

• Focuses on R&D, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other diseases.

• Operates a differentiated drug-conjugate technology platform, OptiDC, with over 30 pipeline programs.

• Employs around 2,000 staff, with significant R&D, manufacturing, and sales teams.

• Strategic partnerships with major global firms, including MSD, to maximize pipeline and corporate value.

• Expanding business landscape and capabilities for global product development and commercialization.

Pipeline highlights and clinical progress

• Four approved products with seven indications; two products at NDA stage; over 10 in clinical development.

• TROP2 ADC (sac-TMT) launched in China in November 2024, first globally approved for lung cancer.

• HER2-ADC approved for HER2-positive breast cancer; cetuximab and PD-L1 also available.

• Multiple pivotal clinical studies ongoing for breast, lung, and GI cancers; data presented at major conferences.

• Three core products included in China's national reimbursement drug list (NRDL 2025).

Product performance and innovation

• sac-TMT demonstrated best-in-class efficacy and safety in phase three trials for lung and breast cancer.

• HER2-ADC showed significant improvement in PFS and ORR compared to T-DM1 in phase three studies.

• GI cancer pipeline includes cetuximab for colorectal cancer and ADCs targeting gastric and pancreatic tumors.

• OptiDC platform enables tailored drug design, novel payloads, and bispecific ADCs for enhanced efficacy.

• Exploring non-oncology ADCs for autoimmune and metabolic diseases, aiming for better safety and efficacy.